Publications by authors named "Thomas Tam Hoang"
Background: Despite infliximab biosimilars becoming widely used in inflammatory bowel disease (IBD) patients, real-world non-medical switching is sparse. A biosimilar non-medical switch was launched in British Columbia in 2019, the first Canadian province to do so, from Remicade to an approved biosimilar (CT-P13 or SB2).
Aims: This study aims to obtain real-world evidence evaluating the clinical outcomes of non-medical switching from Remicade to the infliximab biosimilars.
An Update on Anti-TNF Biosimilar Switching-Real-World Clinical Effectiveness and Safety.
J Can Assoc Gastroenterol
February 2024
Article Synopsis
- Biosimilar medications for inflammatory bowel disease (IBD) are being adopted in Canada to reduce healthcare costs, with a nationwide switch expected to finish by the end of 2023, despite concerns regarding their effectiveness compared to originator products.* -
- A systematic review of 43 studies involving over 7,400 IBD patients showed similar clinical outcomes in those switching to biosimilars as compared to those who continued on originator medications, particularly in terms of maintaining remission.* -
- The results suggest that, while monitoring is still necessary, the efficacy and safety profiles of biosimilars appear reassuring, which could lead to significant healthcare savings in Canada.*